Zorevunersen's Dravet Data Puts SCN1A Gene Regulation Closer to the Clinic

Overview

Dravet syndrome is a severe pediatric epilepsy driven primarily by SCN1A variants that reduce NaV1.1 expression, and standard antiseizure treatment rarely controls either the seizures or the broader developmental symptoms, according to Mayo Clinic.

Zorevunersen is being tested as a gene-regulation therapy rather than a conventional antiseizure drug: it is an antisense oligonucleotide designed to increase expression from the healthy SCN1A copy, and Mayo Clinic and Northwestern University both describe it as targeting the underlying cause of the disease.

What We Know

The dataset highlighted by Northwestern University and Mayo Clinic came from two open-label phase 1/2a studies in the U.S. and U.K. that enrolled 81 patients ages 2 to 18, with eligible participants continuing into open-label extension studies and receiving zorevunersen every four months.

In that follow-up, patients who received 70 mg loading doses and continued into extension dosing saw median seizure-frequency reductions of 58.8 percent to 90.2 percent over the first 20 months, Mayo Clinic reported. Live Science reported similar results, saying the highest-dose group saw 59 percent to 91 percent fewer seizures after 20 months.

The treatment is delivered by lumbar puncture into the cerebrospinal fluid, Mayo Clinic and Live Science reported. Northwestern University said most treatment-emergent adverse events were mild to moderate, while Mayo Clinic noted that the most common issues were elevated cerebrospinal fluid protein and post-lumbar-puncture syndrome, without increased intracranial pressure or hydrocephalus.

What It Means

That combination of seizure reduction and broader developmental gains is why Mayo Clinic described the data as supporting the potential for disease modification in Dravet syndrome, rather than just another symptomatic therapy.

Live Science says a larger randomized phase 3 study is already underway, and that even a positive readout would still leave broad availability years away.

What We Don’t Know

The current evidence is still early and open-label, so it cannot yet prove that zorevunersen will beat placebo in a blinded trial, Live Science noted.

It also remains unclear how durable the benefits will be outside specialized trial settings or how practical repeated spinal dosing will be in routine care, because the drug is administered by lumbar puncture and requires clinic visits for each dose, according to Live Science.